Oncomed Pharmaceuticals Inc (NASDAQ:OMED) has been upgraded to Hold in a report by Zacks Investment Research today.
- Updated: October 15, 2016
Zacks Investment Research has upgraded Oncomed Pharmaceuticals Inc (NASDAQ:OMED) to Hold in a statement released on 10/12/2016.
Previously on Thursday September 22, 2016, HC Wainwright released a statement on Oncomed Pharmaceuticals Inc (NASDAQ:OMED) upped the target price from $0.00 to $20.00. At the time, this indicated a possible upside of 0.68%.
Only yesterday Oncomed Pharmaceuticals Inc (NASDAQ:OMED) traded -1.39% lower at $10.42. OMED’s 50-day average is $11.06 and its 200-day moving average is $11.78. With the last close down -15.56% from the 200-day average, compared with the S&P 500 Index which has decreased -0.01% over the same time. 151,964 shares of the stock were exchanged, down from an avg. volume of 200,380
See Chart Below
Oncomed Pharmaceuticals Inc has with a 52 week low of $8.42 and a 52 week high of $23.98 and has a market cap of $0.
Also covering Oncomed Pharmaceuticals Inc's target, a total of 6 equity analysts have released a research note on the stock. The consensus target price is $18.17 with 2 brokers rating the company a strong buy, three firms rating the stock a buy, 1 equity analyst rating the company a hold, 0 brokers rating the stock a underperform, and finally 0 brokerages rating the stock a sell.
More About Oncomed Pharmaceuticals Inc (NASDAQ:OMED)
OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company's product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc. The Company's Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4), in the Notch signaling pathway. Tarextumab is an antibody that binds to both the Notch2 and Notch3 receptors. Ipafricept is the Company's Wnt pathway modulator. GITRL-Fc is a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor related protein.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.